It is so encouraging to witness the growing acceptance of cannabis as viable medicine to treat multiple conditions and ailments. Over the past 3 1/2 years,while medicating with cannabis, my thoghts turned to the possible use of cannabis during therapy sessions with your therapist. Cannabis does tend to open ones mind to truth and new possibilities. Being honest with yourself just seems to come easier.
With the new interest on psychedelics as possible treatment for certain mental and emotional illnesses the medicine chest for treating the human condition in an ever changing and evolving modern society will surely grow. And that folks will be very positive growth in societal norms.
It is way past time to shed the counter producticve and destructive judgemental forces that have defined cannabis and psychedelics substances for the past 100 years.
On to the eature article...
MjBixDaily - (This story has been updated to reflect another Bruce Linton tie to a psychedelic company.)
Investors as well as cannabis companies and executives are rushing into psychedelics, a multibillion-dollar opportunity that reminds some of the early days of marijuana – although this infant industry could play out much differently.
The potential market opportunity for psychedelics is as much as $100 billion globally, according to Vancouver, British Columbia-based investment banking firm Canaccord Genuity.
Scientists believe psychedelics could help treat a range of mental-health and behavioral issues, including depression, anxiety, post-traumatic stress disorder (PTSD), addiction and attention deficit hyperactivity disorder (ADHD).
The main ingredient, psilocybin, can activate serotonin receptors, stimulating neural activity in the brain and enhancing consciousness.
Studies done since 2016 by Johns Hopkins University in Maryland and other researchers show potential for psychedelics to treat persistent depression.
Here are just a few indicators of the wave of interest in psychedelics:
- In the past year alone, dozens of companies have moved into the space, either as psychedelic-only companies or from other industries such as bioscience, pharmaceuticals and cannabis.
- A number of cannabis scientists in Canada and the U.S. have shifted to psychedelics or are now in both industries.
- Cannabis executives are embracing the trend. For example, former Canopy Growth CEO Bruce Linton is involved in at least two psychedelic companies. He’s chair of the advisory board of the psychedelic mushroom business Red Light Holland as well as a board member and large stockholder of one of the biggest psychedelic companies, New York-based MindMed. MindMed started trading on the Nasdaq on April 27.
Comments
Post a Comment